Voriconazole Aurovitas Spain 200 mg powder for infusion solution EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Voriconazole Aurovitas Spain 200 mg powder for solution for infusion EFG

Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only, and you should not pass it on to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse reactions, consult your doctor, pharmacist or nurse, even if they are adverse reactions not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Voriconazole Aurovitas Spain is and what it is used for
2. What you need to know before using Voriconazole Aurovitas Spain
3. How to use Voriconazole Aurovitas Spain
4. Possible side effects
5. How to store Voriconazole Aurovitas Spain
6. Contents of the pack and other information

1. What Voriconazol Aurovitas Spain is and what it is used for

Voriconazol Aurovitas Spain contains the active substance voriconazole. Voriconazole is an antifungal medicine. It works by killing or preventing the growth of fungi that cause infections.

It is used to treat patients (adults and children aged 2 years and older) with:

• invasive aspergillosis (a type of fungal infection caused by Aspergillus sp.).
• candidaemia (another type of fungal infection caused by Candida sp.) in non-neutropenic patients (patients who do not have an abnormally low white blood cell count).
• serious invasive infections caused by Candida sp. when the fungus is resistant to fluconazole (another antifungal medicine).
• serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi).

Voriconazole is used in patients with serious fungal infections that may be life-threatening.

Prevention of fungal infections in bone marrow transplant recipients at high risk.

This medicine should only be used under medical supervision.

2. What you need to know before using Voriconazol Aurovitas Spain

Do not use Voriconazol Aurovitas Spain

• If you are allergic to voriconazole or to hydroxypropyl-beta-cyclodextrin (included in section 6).

It is very important that you inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription, or herbal medicines.

During treatment with voriconazole, you must not take the following medicines:

• Terfenadine (used for allergies).
• Astemizole (used for allergies).
• Cisapride (used for digestive problems).
• Pimozide (used for mental disorders).
• Quinidine (used for cardiac arrhythmias).
• Ivabradine (used for symptoms of chronic heart failure).
• Rifampicin (used to treat tuberculosis).
• Efavirenz (used to treat HIV) at doses of 400 mg or higher once daily.
• Carbamazepine (used to treat seizures).
• Phenobarbital (used for severe insomnia and seizures).
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine).
• Sirolimus (used in transplant patients).
• Ritonavir (used to treat HIV) at doses of 400 mg or higher twice daily.
• St. John’s wort (Hypericum perforatum, herbal medicine).
• Naloxegol (used to treat constipation specifically caused by opioid analgesics, e.g., morphine, oxycodone, fentanyl, tramadol, codeine).
• Tolvaptan (used to treat hyponatremia [low blood sodium levels] or to slow the decline in kidney function in patients with polycystic kidney disease).
• Lurasidone (used to treat depression).
• Finerenone (used to treat chronic kidney disease).
• Venetoclax (used for the treatment of patients with chronic lymphocytic leukemia [CLL]).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting this medicine if:

• You have had an allergic reaction to other azoles.
• You have or have previously had liver disease. If you have liver disease, your doctor may prescribe a lower dose of voriconazole. Your doctor should also monitor your liver function during treatment with voriconazole by performing blood tests.
• You know you have cardiomyopathy, irregular heartbeat, slow heart rate, or an abnormality on the electrocardiogram (ECG) known as “prolonged QTc syndrome.”

You should avoid any exposure to sunlight and solar radiation during treatment. It is important to cover exposed areas and to use sunscreen with a high sun protection factor (SPF), as your skin may become more sensitive to UV rays from the sun. This sensitivity may be further increased by the use of other medicines that make the skin sensitive to sunlight, such as methotrexate. These precautions also apply to children.

While you are being treated with voriconazole:

• Inform your doctor if you experience:
  • Sunburn
  • Severe skin rash or blisters
  • Bone pain

If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who may consider it important for you to have regular check-ups. There is a small risk of developing skin cancer with long-term use of voriconazole.

If you develop signs of “adrenal insufficiency,” in which the adrenal glands do not produce sufficient amounts of certain steroid hormones, such as cortisol, which may cause symptoms such as: prolonged or chronic fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, inform your doctor.

If you experience signs of “Cushing's syndrome,” in which the body produces too much cortisol hormone, which may cause symptoms such as: weight gain, fatty hump between the shoulders, rounded face, darkening of the skin on the abdomen, thighs, breasts, and arms, thin skin, easy bruising, high blood sugar levels, excessive hair growth, or excessive sweating, inform your doctor.

Your doctor should monitor the function of your liver and kidneys by performing blood tests.

Children and adolescents

Voriconazole must not be given to children under 2 years of age.

Other medicines and Voriconazol Aurovitas Spain

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines, including those obtained without a prescription.

Some medicines, when used at the same time as voriconazole, may affect the action of voriconazole, or voriconazole may affect the action of other medicines.

Inform your doctor if you are taking the following medicines, as concomitant treatment with voriconazole should be avoided if possible:

• Ritonavir (used to treat HIV) at a dose of 100 mg twice daily.
• Glasdegib (used to treat cancer); if you need to take both medicines, your doctor will frequently monitor your heart rhythm.

Inform your doctor if you are taking any of the following medicines, as concomitant treatment with voriconazole should be avoided if possible, and a dose adjustment of voriconazole may be needed:

• Rifabutin (used to treat tuberculosis). If you are already being treated with rifabutin, your blood count and adverse effects of rifabutin should be monitored.
• Phenytoin (used to treat epilepsy). If you are already being treated with phenytoin, the concentration of phenytoin in your blood should be monitored during treatment with voriconazole, and your dose may need to be adjusted.

Tell your doctor if you are taking any of the following medicines, as you may need a dose adjustment or monitoring to ensure these medicines and/or voriconazole are still effective:

• Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol; used to reduce blood clotting).
• Ciclosporin (used in transplant patients).
• Tacrolimus (used in transplant patients).
• Sulfonylureas (e.g., tolbutamide, glipizide, glyburide; used for diabetes).
• Statins (e.g., atorvastatin, simvastatin; used to lower cholesterol levels).
• Benzodiazepines (e.g., midazolam, triazolam; used for severe insomnia and stress).
• Omeprazole (used to treat stomach ulcers).
• Oral contraceptives (if you use this medicine while taking oral contraceptives, you may experience adverse effects such as nausea and menstrual disorders).
• Vinca alkaloids (e.g., vincristine, vinblastine; used to treat cancer).
• Tyrosine kinase inhibitors (e.g., axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib; used to treat cancer).
• Tretinoin (used to treat leukemia).
• Indinavir and other HIV protease inhibitors (used to treat HIV infection).
• Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine; used to treat HIV infection) (some doses of efavirenz cannot be taken at the same time as voriconazole).
• Methadone (used to treat heroin addiction).
• Alfentanil, fentanyl, and other short-acting opioids such as sufentanil (analgesics used during surgery).
• Oxycodone and other long-acting opioids such as hydrocodone (used to treat moderate to severe pain).
• Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac; used to treat pain and inflammation).
• Fluconazole (used to treat fungal infections).
• Everolimus (used to treat advanced kidney cancer and in transplant patients).
• Letermovir (used to prevent cytomegalovirus [CMV] infection after bone marrow transplant).
• Ivacaftor: used to treat cystic fibrosis.
• Flucloxacillin (an antibiotic used for bacterial infections).

Pregnancy and breastfeeding

You must not use voriconazole during pregnancy unless specifically instructed by your doctor. Women of childbearing age being treated with voriconazole should use effective contraception. Contact your doctor immediately if you become pregnant during treatment with voriconazole.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Driving and using machines

Voriconazole may cause blurred vision or discomfort due to increased sensitivity to light. If this occurs, do not drive or operate tools or machinery, and inform your doctor.

Voriconazol Aurovitas Spain contains sodium

This medicine contains approximately 88.74 mg of sodium (a main component of cooking/table salt) per vial. This corresponds to 4.44% of the maximum daily recommended sodium intake for an adult.

Voriconazol Aurovitas Spain contains hydroxypropyl-beta-cyclodextrin

If you have renal impairment, consult your doctor before using this medicine.

3. How to use Voriconazol Aurovitas Spain

Follow exactly the instructions for use of this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.

Your doctor will determine the dose depending on your weight and the type of infection you have.

Your doctor may adjust your dose according to your condition.

The recommended dose in adults (including elderly patients) is as follows:

	Intravenous route
Dose during the first 24 hours (loading dose)	6 mg/kg every 12 hours during the first 24 hours
Dose after the first 24 hours (maintenance dose)	4 mg/kg twice daily

Depending on your response to treatment, your doctor may reduce the dose to 3 mg/kg twice daily.

Your doctor may decide to reduce the dose if you have mild to moderate cirrhosis.

Use in children and adolescents

The recommended dose in children and adolescents is as follows:

	Intravenous route
	Children aged 2 to less than 12 years and adolescents aged 12 to 14 years weighing less than 50 kg	Adolescents aged 12 to 14 years weighing 50 kg or more; and all adolescents older than 14 years
Dose during the first 24 hours (loading dose)	9 mg/kg every 12 hours during the first 24 hours	6 mg/kg every 12 hours during the first 24 hours
Dose after the first 24 hours (maintenance dose)	8 mg/kg twice daily	4 mg/kg twice daily

Depending on your response to treatment, your doctor may increase or decrease the daily dose.

Voriconazol Aurovitas Spain powder for solution for infusion must be reconstituted and diluted to the correct concentration by pharmacy or nursing staff at the hospital (for more information, see the end of this leaflet).

It will be administered by intravenous infusion (into a vein) at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.

If you or your child are using this medicine to prevent fungal infections, your doctor may stop voriconazol administration if you or your child experience adverse effects related to treatment.

If you forget a dose of Voriconazol Aurovitas Spain

Since you will be receiving this medicine under close medical supervision, it is unlikely that you will miss a dose. However, inform your doctor or pharmacist if you think a dose has been missed.

If you interrupt treatment with Voriconazol Aurovitas Spain

Treatment with voriconazol should be maintained for as long as your doctor considers appropriate; however, the duration of treatment with voriconazol powder for solution for infusion should not exceed 6 months.

Patients with weakened immune systems or those with complicated infections may require longer treatment courses to prevent the infection from recurring. Once your condition improves, the intravenous infusion may be replaced with oral tablets.

When your doctor discontinues treatment with voriconazol, you should not experience any effects due to stopping the treatment.

If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

If any occur, they are most likely to be mild and temporary. However, some may be serious and require medical attention.

Serious adverse effects – Stop using voriconazole and contact your doctor:

• Skin rash.
• Jaundice, abnormalities in blood tests monitoring liver function.
• Pancreatitis.

Other adverse effects

Very common: may affect more than 1 in 10 people

• Visual disturbance (changes in vision, including blurred vision, visual color disturbances, abnormal intolerance to visual perception of light, color blindness, eye disorder, visual halos, night blindness, fluctuating vision, perception of sparks, visual aura, decreased visual acuity, visual clarity, partial loss of normal visual field, spots in the visual field).
• Fever.
• Skin rash.
• Nausea, vomiting, and diarrhea.
• Headache.
• Swelling of the limbs.
• Stomach pain.
• Difficulty breathing.
• Elevated liver enzymes.

Common: may affect up to 1 in 10 people

• Sinusitis, gum inflammation, chills, weakness.
• Low blood counts, including severe cases, of certain types of red blood cells (sometimes immune-mediated) or white blood cells (sometimes accompanied by fever), low platelet count affecting blood clotting.
• Low blood sugar levels, low blood potassium levels, low blood sodium levels.
• Anxiety, depression, confusion, agitation, insomnia, hallucinations.
• Seizures, tremors or uncontrolled muscle movements, tingling or abnormal sensations in the skin, increased muscle tone, drowsiness, dizziness.
• Ocular hemorrhage.
• Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting.
• Hypotension, vein inflammation (which may be associated with blood clot formation).
• Acute breathing difficulty, chest pain, facial swelling (mouth, lips, and around the eyes), fluid retention in the lungs.
• Constipation, indigestion, lip inflammation.
• Jaundice (yellowing of the skin), liver inflammation, and liver damage.
• Skin rashes, which may become severe, with blisters and peeling, characterized by flat, red areas covered with small merging bumps, skin redness.
• Itching.
• Alopecia.
• Back pain.
• Kidney failure, presence of blood in urine, abnormalities in kidney function tests.
• Sunburn or severe skin reaction following exposure to light or sun.
• Skin cancer.

Uncommon: may affect up to 1 in 100 people

• Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, gastrointestinal inflammation causing antibiotic-associated diarrhea, inflammation of the lymphatic vessels.
• Inflammation of the thin tissue lining the abdominal wall and covering abdominal organs.
• Enlargement (sometimes painful) of lymph nodes, bone marrow failure, increased eosinophils.
• Reduced adrenal gland function, underactive thyroid gland.
• Abnormal brain function, Parkinson's-like symptoms, nerve damage causing numbness, pain, tingling, or burning sensations in hands or feet.
• Problems with balance or coordination.
• Brain swelling.
• Double vision, serious eye disorders such as eye and eyelid pain and inflammation, abnormal eye movements, optic nerve damage leading to vision disturbances, optic disc inflammation.
• Decreased sensitivity to touch.
• Disturbance of taste sensation.
• Hearing difficulty, tinnitus, vertigo.
• Inflammation of certain internal organs, pancreas and duodenum, swelling and inflammation of the tongue.
• Liver enlargement, liver failure, gallbladder disease, gallstones.
• Joint inflammation, inflammation of veins under the skin (which may be associated with blood clot formation).
• Kidney inflammation, protein in urine, kidney damage.
• Very high heart rate or extrasystoles, sometimes with erratic electrical impulses.
• Abnormal electrocardiogram (ECG).
• Elevated blood cholesterol, elevated blood urea.
• Skin allergic reactions (sometimes severe), such as skin disease, potentially life-threatening causing blisters and painful sores on the skin and mucous membranes, especially in the mouth, skin inflammation, hives, skin redness and irritation, reddish or purplish skin discoloration possibly caused by low platelet count, eczema.
• Reaction at the infusion site.
• Allergic reaction or exaggerated immune response.
• Inflammation of the tissue surrounding the bone.

Rare: may affect up to 1 in 1,000 people

• Overactive thyroid gland.
• Deterioration of brain function as a serious complication of liver disease.
• Loss of most of the optic nerve fibers, corneal opacity, involuntary eye movements.
• Blister formation due to photosensitivity.
• Disorder in which the immune system attacks part of the peripheral nervous system.
• Heart rhythm or conduction problems (sometimes potentially fatal).
• Potentially life-threatening allergic reaction.
• Blood clotting abnormalities.
• Severe skin allergic reactions such as rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa, and submucosal layers, painful and itchy plaques of thickened, red, scaly skin with silvery scales, skin and mucous membrane irritation, potentially life-threatening skin disease causing large portions of the epidermis, the outermost skin layer, to detach from underlying skin layers.
• Small scaly, dry skin patches, sometimes thick with tips or "horns".

Adverse effects with unknown frequency:

• Freckles and pigmented spots.

Other important adverse effects with unknown frequency, but which must be reported to your doctor immediately:

• Red, scaly plaques or ring-shaped skin lesions which may be a sign of an autoimmune disease called cutaneous lupus erythematosus.

During infusion, infrequently, reactions with voriconazole have occurred (including facial flushing, fever, sweating, increased heart rate, and difficulty breathing). Your doctor may stop the infusion if this happens.

Since voriconazole has been observed to affect the liver and kidneys, your doctor should monitor liver and kidney function through blood tests. Inform your doctor if you have stomach pain or if your stools have an unusual consistency.

Cases of skin cancer have been reported in patients treated with voriconazole over long periods.

The frequency of sunburn or severe skin reactions following exposure to light or sun was higher in children. If you or your child develop skin disorders, your doctor may refer you to a dermatologist who, after consultation, may decide that regular monitoring is necessary. Elevated liver enzymes were also observed more frequently in children.

If any of these adverse effects persist or are bothersome, inform your doctor.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if they are possible adverse effects not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Voriconazole Aurovitas Spain

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the label after EXP. The expiry date refers to the last day of the month indicated.

This medicine does not require special storage conditions prior to opening.

Chemical and physical in-use stability has been demonstrated for 72 hours at 25°C and at 2-8°C.

From a microbiological standpoint, once reconstituted, the medicine should be used immediately. If not used immediately, the storage times and conditions prior to use are the responsibility of the user and normally should not exceed 24 hours at 2-8°C (in a refrigerator), unless reconstitution has been carried out under controlled and validated aseptic conditions. The reconstituted medicine must first be diluted with a compatible infusion diluent before administration (for further information, see the end of this leaflet).

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the package and other information

Composition of Voriconazole Aurovitas Spain

• The active substance is voriconazole. Each vial contains 200 mg of voriconazole. After reconstitution, each ml of solution contains 10 mg of voriconazole.
• The other components are hydroxypropyl-beta-cyclodextrin, sodium chloride, and hydrochloric acid (for pH adjustment).

Appearance of the product and contents of the pack

Each pack contains one vial. Voriconazole Aurovitas Spain is presented as a white or almost white lyophilized powder for solution for infusion in a 25 ml type I glass vial, with a grey chlorobutyl rubber stopper and a metallic cap with a red plastic flip-off seal.

Marketing Authorisation Holder

Eugia Pharma (Malta) Limited

Vault 14, Level 2, Valletta Waterfront

Floriana, FRN 1914

Malta

Manufacturer

Pharmathen International S.A.

Sapes Industrial Park, Block 5

69300 Rodopi

Greece

or

Pharmathen S.A.

Dervenakion 6

15351 Pallini

Attikis

Greece

or

Anfarm Hellas S.A

Schimatari Viotias

320 09

Greece

Further information on this medicinal product is available from the local representative of the Marketing Authorisation Holder:

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

This medicinal product is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Germany:	Voriconazole PUREN 200 mg powder for solution for infusion
Croatia:	Voriconazole PharmaS 200 mg powder for infusion solution
Spain:	Voriconazole Aurovitas Spain 200 mg powder for solution for infusion EFG
France:	VORICONAZOLE STRAGEN® 200 mg, powder for solution for infusion
Netherlands:	Voriconazole Pharmathen 200 mg powder for solution for infusion
Poland:	Voriconazole Genoptim 200 mg powder for preparation of infusion solution
United Kingdom (Northern Ireland):	Voriconazole 200 mg powder for solution for infusion

Date of the most recent review of this summary: February 2026.

Detailed information on this medicine is available on the website of the Spanish Agency for Medicinal Products and Health Products (AEMPS) (http://www.aemps.gob.es).

The following information is intended for healthcare professionals only:

Information on reconstitution and dilution

• Voriconazol Aurovitas Spain powder for solution for infusion must first be reconstituted with 19 ml of water for injections or 19 ml of sodium chloride 9 mg/ml (0.9%) for infusion to obtain an extractable volume of 20 ml of a clear concentrate containing 10 mg/ml of voriconazole.
• Discard the Voriconazol Aurovitas Spain vial if the vacuum prevents the solvent from being introduced into the vial.
• The use of a standard 20 ml syringe (not automatic) is recommended to ensure the exact amount (19.0 ml) of water for injections or sodium chloride 9 mg/ml (0.9%) for infusion is dispensed.
• The required volume of reconstituted concentrate is then added to a compatible infusion solution listed below, to obtain a final Voriconazol Aurovitas Spain solution containing 0.5 to 5 mg/ml of voriconazole.
• This medicine is for single use only and any unused solution must be discarded; only clear solutions free from particles should be used.
• It must not be administered as a rapid intravenous injection.
• For information on storage, see section 5 “Storage of Voriconazol Aurovitas Spain”.

Voriconazol Aurovitas Spain is a sterile, single-dose lyophilized product without preservatives. Therefore, from a microbiological standpoint, the reconstituted solution should be used immediately. If not used immediately, the storage times and conditions prior to use are the responsibility of the user and normally should not exceed 24 hours at 2–8°C (in a refrigerator), unless reconstitution has been carried out under controlled and validated aseptic conditions. Voriconazol Aurovitas Spain must first be diluted with a compatible solution before infusion.

Compatible infusion solutions

The reconstituted solution may be diluted with:

Sodium chloride 9 mg/ml (0.9%) injection solution

Compound sodium lactate intravenous infusion solution

5% glucose intravenous infusion solution and Ringer's lactate

5% glucose and 0.45% sodium chloride intravenous infusion solution

5% glucose intravenous infusion solution

5% glucose intravenous infusion solution with 20 mEq potassium chloride

0.45% sodium chloride intravenous infusion solution

5% glucose and sodium chloride 9 mg/ml (0.9%) injectable solution

The compatibility of voriconazole with other diluents different from those described above (or mentioned below under “Incompatibilities”) is unknown.

Incompatibilities

Voriconazol Aurovitas Spain must not be infused through the same line or cannula simultaneously with other drug infusions, including parenteral nutrition (e.g., Aminofusin 10% Plus).

Hemoderived products must not be infused simultaneously during administration of Voriconazol Aurovitas Spain.

Total parenteral nutrition may be administered simultaneously with Voriconazol Aurovitas Spain, but not through the same line or cannula.

Voriconazol Aurovitas Spain must not be diluted with 4.2% sodium bicarbonate solution.

Required volumes of voriconazole 10 mg/ml concentrate

Body weight (kg)	Volume of concentrated voriconazole (10 mg/ml) required for:
	Dose of 3 mg/kg (number of vials)	Dose of 4 mg/kg (number of vials)	Dose of 6 mg/kg (number of vials)	Dose of 8 mg/kg (number of vials)	Dose of 9 mg/kg (number of vials)
10	-	4.0 ml (1)	-	8.0 ml (1)	9.0 ml (1)
15	-	6.0 ml (1)	-	12.0 ml (1)	13.5 ml (1)
20	-	8.0 ml (1)	-	16.0 ml (1)	18.0 ml (1)
25	-	10.0 ml (1)	-	20.0 ml (1)	22.5 ml (2)
30	9.0 ml (1)	12.0 ml (1)	18.0 ml (1)	24.0 ml (2)	27.0 ml (2)
35	10.5 ml (1)	14.0 ml (1)	21.0 ml (2)	28.0 ml (2)	31.5 ml (2)
40	12.0 ml (1)	16.0 ml (1)	24.0 ml (2)	32.0 ml (2)	36.0 ml (2)
45	13.5 ml (1)	18.0 ml (1)	27.0 ml (2)	36.0 ml (2)	40.5 ml (3)
50	15.0 ml (1)	20.0 ml (1)	30.0 ml (2)	40.0 ml (2)	45.0 ml (3)
55	16.5 ml (1)	22.0 ml (2)	33.0 ml (2)	44.0 ml (3)	49.5 ml (3)
60	18.0 ml (1)	24.0 ml (2)	36.0 ml (2)	48.0 ml (3)	54.0 ml (3)
65	19.5 ml (1)	26.0 ml (2)	39.0 ml (2)	52.0 ml (3)	58.5 ml (3)
70	21.0 ml (2)	28.0 ml (2)	42.0 ml (3)	-	-
75	22.5 ml (2)	30.0 ml (2)	45.0 ml (3)	-	-
80	24.0 ml (2)	32.0 ml (2)	48.0 ml (3)	-	-
85	25.5 ml (2)	34.0 ml (2)	51.0 ml (3)	-	-
90	27.0 ml (2)	36.0 ml (2)	54.0 ml (3)	-	-
95	28.5 ml (2)	38.0 ml (2)	57.0 ml (3)	-	-
100	30.0 ml (2)	40.0 ml (2)	60.0 ml (3)	-	-